中国医师进修杂志
中國醫師進脩雜誌
중국의사진수잡지
CHINESE JOURNAL OF POSTGRADUATES OF MEDICINE
2012年
25期
29-31
,共3页
赵鹏%项小平%周士海%曹秋云
趙鵬%項小平%週士海%曹鞦雲
조붕%항소평%주사해%조추운
糖尿病神经病变%治疗结果%普瑞巴林%加巴喷丁
糖尿病神經病變%治療結果%普瑞巴林%加巴噴丁
당뇨병신경병변%치료결과%보서파림%가파분정
Diabetic neuropathies%Treatment outcome%Pregabalin%Gabapentin
目的 比较普瑞巴林和加巴喷丁对糖尿病周围神经痛的疗效及安全性.方法 将60例糖尿病周围神经痛患者按随机数字表法分为普瑞巴林组(30例)和加巴喷丁组(30例),分别给予普瑞巴林和加巴喷丁治疗4周.用视觉模拟量表(VAS)评分进行临床疗效评定,观察不良反应的发生情况.结果 普瑞巴林组和加巴喷丁组治疗后1、2、4周末VAS评分[(4.05±0.93)、(2.73±0.72)、(2.06±0.58)分和(5.42±0.88)、( 2.93±0.80)、(2.19±0.64)分]均较治疗前[(7.45±0.82)分和(7.68±0.84)分]显著下降(P＜0.01),治疗后1周末普瑞巴林组VAS评分较加巴喷丁组显著下降(P＜0.01),两组治疗后2、4周末VAS评分比较差异无统计学意义(P＞0.05).两组治疗后4周末有效率比较差异无统计学意义(P＞0.05).普瑞巴林组不良反应发生率[16.67％％(5/30)]明显低于加巴喷丁组[36.67％(11/30)] (P＜ 0.01).结论 普瑞巴林与加巴喷丁治疗糖尿病周围神经痛疗效相当,但起效更快,不良反应更小.
目的 比較普瑞巴林和加巴噴丁對糖尿病週圍神經痛的療效及安全性.方法 將60例糖尿病週圍神經痛患者按隨機數字錶法分為普瑞巴林組(30例)和加巴噴丁組(30例),分彆給予普瑞巴林和加巴噴丁治療4週.用視覺模擬量錶(VAS)評分進行臨床療效評定,觀察不良反應的髮生情況.結果 普瑞巴林組和加巴噴丁組治療後1、2、4週末VAS評分[(4.05±0.93)、(2.73±0.72)、(2.06±0.58)分和(5.42±0.88)、( 2.93±0.80)、(2.19±0.64)分]均較治療前[(7.45±0.82)分和(7.68±0.84)分]顯著下降(P＜0.01),治療後1週末普瑞巴林組VAS評分較加巴噴丁組顯著下降(P＜0.01),兩組治療後2、4週末VAS評分比較差異無統計學意義(P＞0.05).兩組治療後4週末有效率比較差異無統計學意義(P＞0.05).普瑞巴林組不良反應髮生率[16.67％％(5/30)]明顯低于加巴噴丁組[36.67％(11/30)] (P＜ 0.01).結論 普瑞巴林與加巴噴丁治療糖尿病週圍神經痛療效相噹,但起效更快,不良反應更小.
목적 비교보서파림화가파분정대당뇨병주위신경통적료효급안전성.방법 장60례당뇨병주위신경통환자안수궤수자표법분위보서파림조(30례)화가파분정조(30례),분별급여보서파림화가파분정치료4주.용시각모의량표(VAS)평분진행림상료효평정,관찰불량반응적발생정황.결과 보서파림조화가파분정조치료후1、2、4주말VAS평분[(4.05±0.93)、(2.73±0.72)、(2.06±0.58)분화(5.42±0.88)、( 2.93±0.80)、(2.19±0.64)분]균교치료전[(7.45±0.82)분화(7.68±0.84)분]현저하강(P＜0.01),치료후1주말보서파림조VAS평분교가파분정조현저하강(P＜0.01),량조치료후2、4주말VAS평분비교차이무통계학의의(P＞0.05).량조치료후4주말유효솔비교차이무통계학의의(P＞0.05).보서파림조불량반응발생솔[16.67％％(5/30)]명현저우가파분정조[36.67％(11/30)] (P＜ 0.01).결론 보서파림여가파분정치료당뇨병주위신경통료효상당,단기효경쾌,불량반응경소.
Objective To compare the efficacy and safety of pregabalin and gabapentin in treatment of patients with diabetic peripheral neuropathic pain.Methods Sixty patients with diabetic peripheral neuropathic pain were allocated into pregabalin group (30 cases ) and gabapentin group (30 cases) for a 4-week period treatment by random digits table method.The efficacy was measured with visual analogue scale (VAS) score,while the side effects were evaluated.Results VAS score in both groups was significantly lower at the end of 1st,2nd or 4th week after treatment than that before treatment [pregabalin group:( 4.05 ±0.93),(2.73 ±0.72),(2.06 ±0.58) scores vs.(7.45 ±0.82) scores; gabapentin group:(5A2 ±0.88),(2.93 ± 0.80),(2.19 ± 0.64) scores vs.(7.68 ± 0.84) scores] (P ＜ 0.01 ).VAS score in pregabalin group was lower than that in gabapentin group at the end of 1st week significantly (P＜ 0.01 ).Not only there was no significant difference in VAS score at the end of 2nd or 4th week between two groups,but also in response rates at the end of 4th week (P ＞ 0.05 ).The rate of adverse reaction in pregabalin group was significantly lower than that in gabapentin group [16.67％ (5/30) vs.36.67％( 11/30)] ( P ＜ 0.01 ).Conclusion Pregabalin is as effective as gabapentin in treatment of patients with diabetic peripheral neuropathic pain,but it has faster effect and less adverse events than gabapentin.
